UPDATE: Catalent Says Will Accelerate Qualification, Scale-Up Of Added High-Speed Vial-Filling Line, Expected To Be Operational In Q4'21, Expanded Deal Will Support Production Of J&J's Janssen Vaccine Through Late 2022